IP Library Granted Patent US 9,132,186
Granted Patent B2
US 9,132,186 · App. 13/908,766 · Granted Sep 15, 2015

Reduction of concomitant infections in pigs by the use of PCV2 antigen

Inventors: Vicky Fachinger (Bad Soden, DE); Knut Elbers (Mittelbiberach, DE); Marion Kixmoeller (Munich, DE)
Assignee: Boehringer Ingelheim Vetmedica, Inc.
A61K39/12A61K45/06A61K2039/552C12N2750/10034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,186
App. No.
13/908,766
Granted
Sep 15, 2015
Kind
B2
Abstract

The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen.

Claims (4)

1. A method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by one or more pathogens other than PCV2 comprising the step administering to said pig(s) a single dose of an immunogenic composition comprising 4-400 μg of PCV2 ORF2 antigen and at least one further component selected from the group consisting of inactivated viral vector, cell culture supernate, media, viral inactivators, neutralization agents for viral inactivators, antibiotics, and combinations thereof, wherein the number of pigs infected with one or more of the pathogens other than PCV2 is reduced with regard to one or more of the pathogens by more than 10% after a single dose of the immunogenic composition comprising PCV2 ORF2 when compared to those pigs not receiving the PCV2 ORF2 composition, and wherein the concomitant infections are selected from the group of consisting of Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Strepococcus suis , porcine reproductive and respiratory syndrome virus (PRRSV), and combinations thereof.

2. The method according to claim 1 , characterized in that the pigs or the herd of pigs are/is infected with PCV2.

3. A method for improving the resistance of pigs against concomitant infections with one or more pathogens other than PCV2, comprising the step administering to said pig(s) a single dose of an immunogenic composition comprising 4-400 μg of PCV2 ORF2 antigen and at least one further component selected from the group consisting of inactivated viral vector, cell culture supernate, media, viral inactivators, neutralization agents for viral inactivators, antibiotics, and combinations thereof, wherein the number of pigs infected with one or more of the pathogens other than PCV2 is reduced with regard to one of more of the pathogens by more than 10% after a single dose of the immunogenic composition comprising PCV2 ORF2 when compared to those pigs not receiving the PCV2 ORF2 composition, and wherein the concomitant infections are selected from the group consisting of Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Strepococcus suis , porcine reproductive and respiratory syndrome virus (PRRSV), and combinations thereof.

4. The method according to claim 3 , characterized in that the pigs are infected with PCV2.

Priority Claims (1)
EP 07115609 · Sep 4, 2007 · regional
Continuity (3)
Continuation 12941836 · Nov 8, 2010
Continuation 12198721 · Aug 26, 2008
Related Publication 20130302370A1 · Nov 14, 2013